Jonathan M Michel1,2, Antonio H Frangieh1,3, Daniele Giacoppo1,4,5,6, Hector A Alvarez-Covarrubias1,7, Costanza Pellegrini1, Tobias Rheude1, Oliver Deutsch1, N Patrick Mayr1, P Moritz Rumpf1,2, Barbara E Stähli2, Adnan Kastrati1,8, Heribert Schunkert1,8, Erion Xhepa1, Michael Joner1,8, A Markus Kasel9,10. 1. German Heart Centre Munich, Technical University Munich, Munich, Germany. 2. Department of Cardiology, University Heart Center, University Hospital Zurich, Zurich, Switzerland. 3. Department of Cardiology, Hôtel-Dieu de France University Hospital, Saint-Joseph University of Beirut, Beirut, Lebanon. 4. Department of Cardiology, Alto Vicentino Hospital, Santorso, Italy. 5. Department of Cardiac-Thoracic-Vascular Sciences, University of Padua, Padua, Italy. 6. Cardiovascular Research Institute, Royal College of Surgeons in Ireland, Dublin, Ireland. 7. Hospital de Cardiología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, México. 8. Deutsches Zentrum Für Herz- Und Kreislauf-Forschung (DZHK) E.V. (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany. 9. German Heart Centre Munich, Technical University Munich, Munich, Germany. markus_kasel@web.de. 10. Department of Cardiology, University Heart Center, University Hospital Zurich, Zurich, Switzerland. markus_kasel@web.de.
Abstract
BACKGROUND: Bicuspid aortic valve may be associated with increased complications during transcatheter aortic valve implantation (TAVI). AIMS: Compare balloon-expandable transcatheter heart valve (THV) safety and efficacy in severe tricuspid (TAV) and bicuspid (BAV) aortic stenosis. METHODS: Transfemoral TAVI was performed in 743 patients (Jan 2014-June 2019) using the SAPIEN 3 THV. Aortic valve morphology was determined using computed tomography. Valve Academic Research Consortium-2 (VARC-2) derived safety and efficacy endpoints at 1 year were evaluated. RESULTS: BAV patients (n = 78), were younger (77 [72, 81] vs. 81 [78, 85] years, p < 0.001) with lower surgical risk (EuroSCORE II 2.96% vs. 4.51% p < 0.001). Bicuspid valves were more calcified (BAV 1308mm3, TAV 848mm3 p < 0.001) with more asymmetric calcification (BAV 63/78 (81%), TAV 239/665 (36%), p < 0.001). Device success (BAV 94%, TAV 90%, p = 0.45) and major vascular complications (BAV 6%, TAV 9%, p = 0.66) were comparable. At 1 year, there was a trend toward lower combined all-cause mortality and rehospitalization for congestive heart failure in BAV patients (BAV 7%, TAV 13%, p = 0.08) with significantly lower all-cause mortality in this cohort (BAV 1%, TAV 9%, p = 0.020). VARC-2 time-related valve safety (BAV 22%, TAV 20%, p = 0.60) was comparable; however, bioprosthetic valve thrombosis remained more common in BAV patients (BAV 7%, TAV 2%, p = 0.010, Hazard ratio 3.57 [95% confidence interval 1.26, 10.10]). After propensity score matching, only bioprosthetic valve thrombosis remained significantly different. CONCLUSIONS: Safety and efficacy of the SAPIEN 3 balloon-expandable THV in BAV is comparable with TAV. Higher rates of bioprosthetic valve thrombosis require further investigation.
BACKGROUND: Bicuspid aortic valve may be associated with increased complications during transcatheter aortic valve implantation (TAVI). AIMS: Compare balloon-expandable transcatheter heart valve (THV) safety and efficacy in severe tricuspid (TAV) and bicuspid (BAV) aortic stenosis. METHODS: Transfemoral TAVI was performed in 743 patients (Jan 2014-June 2019) using the SAPIEN 3 THV. Aortic valve morphology was determined using computed tomography. Valve Academic Research Consortium-2 (VARC-2) derived safety and efficacy endpoints at 1 year were evaluated. RESULTS: BAV patients (n = 78), were younger (77 [72, 81] vs. 81 [78, 85] years, p < 0.001) with lower surgical risk (EuroSCORE II 2.96% vs. 4.51% p < 0.001). Bicuspid valves were more calcified (BAV 1308mm3, TAV 848mm3 p < 0.001) with more asymmetric calcification (BAV 63/78 (81%), TAV 239/665 (36%), p < 0.001). Device success (BAV 94%, TAV 90%, p = 0.45) and major vascular complications (BAV 6%, TAV 9%, p = 0.66) were comparable. At 1 year, there was a trend toward lower combined all-cause mortality and rehospitalization for congestive heart failure in BAV patients (BAV 7%, TAV 13%, p = 0.08) with significantly lower all-cause mortality in this cohort (BAV 1%, TAV 9%, p = 0.020). VARC-2 time-related valve safety (BAV 22%, TAV 20%, p = 0.60) was comparable; however, bioprosthetic valve thrombosis remained more common in BAV patients (BAV 7%, TAV 2%, p = 0.010, Hazard ratio 3.57 [95% confidence interval 1.26, 10.10]). After propensity score matching, only bioprosthetic valve thrombosis remained significantly different. CONCLUSIONS: Safety and efficacy of the SAPIEN 3 balloon-expandable THV in BAV is comparable with TAV. Higher rates of bioprosthetic valve thrombosis require further investigation.
Authors: Martin B Leon; Craig R Smith; Michael Mack; D Craig Miller; Jeffrey W Moses; Lars G Svensson; E Murat Tuzcu; John G Webb; Gregory P Fontana; Raj R Makkar; David L Brown; Peter C Block; Robert A Guyton; Augusto D Pichard; Joseph E Bavaria; Howard C Herrmann; Pamela S Douglas; John L Petersen; Jodi J Akin; William N Anderson; Duolao Wang; Stuart Pocock Journal: N Engl J Med Date: 2010-09-22 Impact factor: 91.245
Authors: Femi Philip; Nadine Nadar Faza; Paul Schoenhagen; Milind Y Desai; E Murat Tuzcu; Lars G Svensson; Samir R Kapadia Journal: Catheter Cardiovasc Interv Date: 2015-04-24 Impact factor: 2.692
Authors: Sung-Han Yoon; Won-Keun Kim; Abhijeet Dhoble; Stephan Milhorini Pio; Vasilis Babaliaros; Hasan Jilaihawi; Thomas Pilgrim; Ole De Backer; Sabine Bleiziffer; Flavien Vincent; Tobias Shmidt; Christian Butter; Norihiko Kamioka; Lena Eschenbach; Matthias Renker; Masahiko Asami; Mohamad Lazkani; Buntaro Fujita; Antoinette Birs; Marco Barbanti; Ashish Pershad; Uri Landes; Brad Oldemeyer; Mitusnobu Kitamura; Luke Oakley; Tomoki Ochiai; Tarun Chakravarty; Mamoo Nakamura; Philip Ruile; Florian Deuschl; Daniel Berman; Thomas Modine; Stephan Ensminger; Ran Kornowski; Rudiger Lange; James M McCabe; Mathew R Williams; Brian Whisenant; Victoria Delgado; Stephan Windecker; Eric Van Belle; Lars Sondergaard; Bernard Chevalier; Michael Mack; Jeroen J Bax; Martin B Leon; Raj R Makkar Journal: J Am Coll Cardiol Date: 2020-09-01 Impact factor: 24.094
Authors: Riti Mahadevia; Alex J Barker; Susanne Schnell; Pegah Entezari; Preeti Kansal; Paul W M Fedak; S Chris Malaisrie; Patrick McCarthy; Jeremy Collins; James Carr; Michael Markl Journal: Circulation Date: 2013-12-17 Impact factor: 29.690